China
Africa
Explore chapters and articles related to this topic
Biapenem, Ritipenem, Panipenem, and Sulopenem
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
In Japanese trials for the treatment of patients with chronic lower respiratory tract infection and bacterial pneumonia, biapenem showed clinical and bacteriological efficacy similar to that of imipenem (Matsumoto et al., 1995a; Matsumoto et al., 1995b). In studies of the efficacy of biapenem 150 mg twice daily and 300 mg twice daily given for up to 14 days, the clinical efficacy was 100% (10 of 10 patients) and 90% (9 of 10 patients), respectively (Matsumoto et al., 2000). In Japan, biapenem is used for sepsis, lower respiratory infection, complicated urinary tract infection, peritonitis, and gynecological intrapelvic infection.
Therapeutic drug monitoring of carbapenem antibiotics in critically ill patients: an overview of principles, recommended dosing regimens, and clinical outcomes
Published in Expert Review of Clinical Pharmacology, 2023
Gavin Matthew Joynt, Lowell Ling, Wai Tat Wong, Jeffrey Lipman
We performed a literature search on the electronic database PubMed for articles published in English before August 2022, using the following strategy: Therapeutic ((drug monitoring) OR (Drug Monitoring)) AND ((critically ill) OR (Critical illness) OR (intensive care) OR (critical care)) AND ((carbapenem) OR (imipenem) OR (meropenem) OR (ertapenem) OR (doripenem) OR (betamipron) OR (biapenem) OR (panipenem) OR (tebipenem)). We identified 359 articles, and after screening the title and abstract, full text of 106 articles was reviewed. Articles were included in this review if they were relevant to the key principles of TDM, including the theoretical construct of TDM, PK/PD considerations, carbapenem assay techniques, minimum inhibitory concentration (MIC) interpretation, the clinical application of TDM, and the assessment of relevant outcomes. Articles were excluded if they were not related to TDM or not focused on carbapenems (Figure 1). Only articles published in English were included. We extracted the best evidence currently available, with preference given to clinical studies with robust study designs that reported patient data.